Bailey, Kayleen http://orcid.org/0000-0002-8193-642X
Pandit-Taskar, Neeta
Humm, John L.
Zanzonico, Pat
Gilheeney, Stephen
Cheung, Nai-Kong V.
Kramer, Kim http://orcid.org/0000-0002-3803-878X
Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
Article History
Received: 20 December 2018
Accepted: 26 February 2019
First Online: 16 March 2019
Compliance with ethical standards
:
: Dr. N.K. Cheung reports: receiving commercial research grants from Y-mabs Therapeutics and Abpro-Labs Inc., holding ownership interest/equity in Y-Mabs Therapeutics Inc., holding ownership interest/equity in Abpro-Labs, and owning stock options in Eureka Therapeutics. NKC is the inventor and owner of issued patents licensed by MSK to Ymabs Therapeutics, Biotec pharmacon, and Abpro-labs. NKC is a consultant/advisory board member for Abpro-Labs and Eureka Therapeutics. Dr. Pat Zanzonico is the inventor on a patent pending for systems and methods for determining optimum patient-specific antibody dose for tumor targeting. Dr. Kim Kramer is a consultant to Ymabs Therapeutics Inc. 8H9 is currently licensed to Ymabs Therapeutics. Data in this report was acquired prior to their sponsorship of this study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: There were no animals involved.